MYOVIEW Drug Patent Profile

When do Myoview patents expire, and what generic alternatives are available?

Myoview is a drug marketed by Medi-physics and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in MYOVIEW is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

DrugPatentWatch^® Generic Entry Outlook for Myoview

Myoview was eligible for patent challenges on February 9, 2000.

Indicators of Generic Entry

Summary for MYOVIEW

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Drug Prices:	Drug price information for MYOVIEW
What excipients (inactive ingredients) are in MYOVIEW?	MYOVIEW excipients list
DailyMed Link:	MYOVIEW at DailyMed

See drug prices for MYOVIEW

Recent Clinical Trials for MYOVIEW

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Pharma Inc	Phase 2
GE Healthcare	Phase 4

See all MYOVIEW clinical trials

US Patents and Regulatory Information for MYOVIEW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-001	Feb 9, 1996		RX	Yes	Yes
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-002	Jul 7, 2005		RX	Yes	Yes	9,549,999		Y

Expired US Patents for MYOVIEW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-001	Feb 9, 1996	5,045,302

International Patents for MYOVIEW

See the table below for patents covering MYOVIEW around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0337654	Ligands et leurs complexes avec le technétium-99m (Ligands and cationic complexes thereof with technetium-99m)
China	1024013
Denmark	171416
South Korea	0149439
United Kingdom	8808414
China	1031828
Austria	133956

Supplementary Protection Certificates for MYOVIEW

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

MYOVIEW Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for MYOVIEW

Overview of MYOVIEW

MYOVIEW, a radioactive diagnostic agent, is used primarily for myocardial perfusion imaging and ventricular function studies. It is crucial in the diagnosis and management of coronary artery disease and other cardiac conditions.

Market Growth and Projections

The MYOVIEW market has experienced significant growth in recent years and is projected to continue this upward trend from 2023 to 2031. Here are some key points:

• Rapid Expansion: The market has shown a swift and substantial surge, indicating robust growth rates expected throughout the forecast period[1].
• Segmentation: The market is categorized by type (5 ml, 30 ml) and application (Hospital, Clinic), as well as geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa)[1].

Market Dynamics

Drivers

• Increasing Demand for Diagnostic Imaging: The growing need for accurate and early diagnosis of cardiac diseases drives the demand for MYOVIEW. Advances in medical technology and the increasing prevalence of heart diseases contribute to this trend[1].
• Advancements in Healthcare Infrastructure: Improvements in healthcare facilities, especially in hospitals and clinics, enhance the capacity to use advanced diagnostic tools like MYOVIEW[1].

Restraints

• Regulatory Challenges: Strict regulations and safety measures associated with radioactive drugs can limit market growth. Handling and safety protocols must be strictly adhered to, which can increase costs and complexity[4].
• Competition from Alternative Diagnostics: The presence of other diagnostic agents and imaging techniques, such as Thallium-201 SPECT imaging, can pose competition to MYOVIEW[4].

Opportunities

• Emerging Markets: The Asia-Pacific and other emerging regions offer significant growth opportunities due to their expanding healthcare sectors and increasing demand for advanced diagnostic tools[1].
• Technological Innovations: Integration of MYOVIEW with advanced imaging technologies, such as AI and machine learning, can enhance its efficacy and appeal[5].

Challenges

• Economic Factors: Economic fluctuations and budget constraints in healthcare systems can affect the adoption rate of MYOVIEW. Pharmerging markets, in particular, face challenges due to slowed economic growth and currency devaluations[3].
• Safety and Adverse Reactions: The drug's adverse reaction profile, including rash, urticaria, and allergic reactions, can impact its market acceptance and usage[4].

Financial Trajectory

Revenue Projections

• The MYOVIEW market is expected to see substantial revenue growth from 2023 to 2031, driven by increasing demand and expanding market segments[1].

Key Financial Metrics

• Revenue Growth: The market is projected to grow significantly, with revenue measured in USD million across various segments[1].
• Company Performance: Major players like GE Healthcare, which is involved in the production and distribution of MYOVIEW, have shown strong financial performance. GE Healthcare has delivered adjusted EBIT margin expansions and has a robust pipeline of innovation, contributing to the overall financial health of the market[5].

Competitive Landscape

• The competitive landscape is dominated by a few key players, with GE Healthcare being a prominent one. These companies are evaluated based on their product offerings, financial statements, strategic approaches, and geographical penetration[1].
• Market Share and Rankings: The top companies in the market are ranked based on their market share, recent activities, collaborations, mergers and acquisitions, and new product introductions[1].

Industry Insights and Trends

Global Healthcare Spending

• Global medicine spending, including diagnostic agents like MYOVIEW, is expected to grow, driven by the adoption of new breakthrough medicines and increased volume in pharmerging markets[3].

Technological Advancements

• The integration of AI and machine learning in medical devices, including those used for MYOVIEW imaging, is a significant trend. This enhances the precision and efficiency of diagnostic procedures[5].

Quotes from Industry Experts

"The increasing demand for accurate and early diagnosis of cardiac diseases is driving the growth of the MYOVIEW market. Advances in medical technology and the growing prevalence of heart diseases are key factors contributing to this trend." - Market Research Intellect Report[1].

Illustrative Statistics

• Market Size: The MYOVIEW market is expected to grow significantly, with projections indicating a substantial expansion from 2023 to 2031[1].
• Revenue Growth Rate: The market is anticipated to grow at robust rates, driven by increasing demand and expanding market segments[1].
• Global Medicine Spending: Global medicine spending is projected to reach nearly $1.5 trillion by 2021, with a growth rate of 4-7% CAGR over the next five years[3].

Key Takeaways

• The MYOVIEW market is poised for significant growth driven by increasing demand for diagnostic imaging and advancements in healthcare infrastructure.
• The market faces challenges such as regulatory hurdles and competition from alternative diagnostics.
• Technological innovations and emerging markets offer substantial opportunities for growth.
• Major players like GE Healthcare play a crucial role in the market's financial trajectory.

FAQs

What is MYOVIEW used for?

MYOVIEW is used primarily for myocardial perfusion imaging and ventricular function studies to diagnose and manage coronary artery disease and other cardiac conditions.

Who are the major players in the MYOVIEW market?

Major players include GE Healthcare, which is a prominent company involved in the production and distribution of MYOVIEW.

What are the key drivers of the MYOVIEW market?

Key drivers include the increasing demand for diagnostic imaging, advancements in healthcare infrastructure, and emerging markets.

What are the main challenges facing the MYOVIEW market?

Challenges include regulatory hurdles, competition from alternative diagnostics, and economic factors such as budget constraints in healthcare systems.

How is the MYOVIEW market expected to grow in the future?

The market is expected to grow significantly from 2023 to 2031, driven by increasing demand and expanding market segments, with robust revenue growth projections.

Sources

1. Market Research Intellect - Global Myoview Market Size, Scope And Forecast Report
2. GE HealthCare - Investor Day Presentation
3. IQVIA - Outlook for Global Medicines through 2021
4. FDA - MYOVIEW Injection Label
5. GE HealthCare - Delivering precision care through innovation